sponsored
PatientsVille.com Logo

PatientsVille

Thalidomide Medical Research Studies

Up-to-date List of Thalidomide Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Thalidomide Medical Research Studies

Rank Status Study
1 Recruiting Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer
Condition: Esophageal Cancer
Interventions: Other: chemoradiotherapy;   Drug: Thalidomide;   Other: without Thalidomide
Outcome Measures: Treatment efficacy;   Overall survival (OS);   Local progression-free survival (LPFS);   Safety
2 Recruiting High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP
Condition: Immune Thrombocytopenia
Interventions: Drug: Dexamethasone;   Drug: Thalidomide
Outcome Measure: Evaluation of platelet response
3 Unknown  Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance
Condition: Hepatitis C
Intervention: Drug: Thalidomide
Outcome Measures: Virological response at week 12;   Sustained virological response 24 weeks after the end of therapy;   Safety of using Thalidomide together with SOC.
4 Unknown  Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Drug: Thalidomide;   Drug: TACE
Outcome Measures: Overall survival;   time to progression
5 Recruiting Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
Condition: Myeloma
Interventions: Drug: Thalidomide;   Drug: Lenalidomide;   Behavioral: Questionnaires
Outcome Measure: Response Rate (RR)
6 Recruiting Thalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt Failure
Condition: Congestive Heart Failure
Interventions: Drug: Thalidomide;   Drug: Placebo
Outcome Measures: Changes in left ventricular ejection fraction;   Changes in NYHA functional class
7 Recruiting Velcade (Bortezomib) Consolidation After Transplant
Condition: Multiple Myeloma
Interventions: Drug: Thalidomide;   Drug: Bortezomib
Outcome Measures: The number and percent of patients with complete response (CR) + very good partial response (VGPR);   Complete response (CR) rate;   Stringent complete response (sCR) rate;   Progression-free survival (PFS) rate;   Disease-free survival (DFS) rate;   Overall survival (OS) rate
8 Not yet recruiting Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation
Condition: Coronary Artery Disease
Interventions: Drug: Thalidomide;   Drug: Placebo
Outcome Measures: Occurrence of binary restenosis 6 months after PCI;   Major adverse cardiac events 6 months after PCI
9 Recruiting Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Condition: Relapsed and/or Refractory Multiple Myeloma
Interventions: Biological: Elotuzumab;   Biological: Thalidomide;   Biological: Dexamethasone;   Biological: Cyclophosphamide
Outcome Measures: Proportion of subjects who experience one or more severe (Grade 3 or higher) non-hematologic adverse events;   Proportion of subjects who experience one or more dose reductions or discontinuation of study treatment due to drug related adverse events
10 Not yet recruiting Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Thalidomide Celgene™
Outcome Measure: Pharmacokinetic parameters for plasma Thalidomide: Tmax Cmax AUC t1/2 CL/F V/F
11 Recruiting Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Recurrence
Intervention: Drug: Thalidomide
Outcome Measures: disease-free survival;   Overall survival
12 Unknown  Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer
Condition: Colon Cancer
Intervention: Drug: Thalidomide and UFUR
Outcome Measures: Overall response(CR+PR) and Clinical benefit (CR+PR+SD);   To determine the progression free survival, overall survival (OS)and assess the safety profile
13 Unknown  Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Liver Cancer
Intervention: Drug: Thalidomide
Outcome Measures: progress free survival;   morbility;   overall survival;   recurrence rate
14 Unknown  Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia
Conditions: Hereditary Hemorrhagic Telangiectasia;   Epistaxis
Intervention: Drug: Thalidomide
Outcome Measures: Percentage of patients showing a decrease in the frequency, intensity and duration of epistaxis and in the blood transfusion requirement.;   Size and number of telangiectasias evaluated by endoscopy of nasal mucosa (recording images of the size and localization of telangiectasias);   Minimum dose of the drug that reduces bleeding;   Time to response;   Time to relapse after the end of treatment;   Number of adverse events;   Correlations between biological parameters, response to treatment and side effects profile
15 Recruiting Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Thalidomide;   Drug: lenalidomide;   Biological: rituximab
Outcome Measure: number of patients who experience a response (complete or partial) to treatment
16 Unknown  Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Drug: Thalidomide
Outcome Measures: The primary endpoint is the feasibility and tolerability of Thalidomide plus radiotherapy.;   The secondary end point is correlation of parameters of tumor perfusion assessed by DCEMRI and serum cytokine levels with objective tumor response.
17 Unknown  Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome)
Condition: Myelodysplastic Syndrome
Intervention: Drug: 5-aza-cytidine and Thalidomide
Outcome Measures: overall response rate measured by complete blood counts and bone marrow examinations;   overall response rate;   *safety *hematological improvement *cytogenetic response *progression free survival * Quality of life assessment (FACT: MDS and peripheral neuropathy QOL Questionnaires).
18 Recruiting PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
Condition: Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
Interventions: Drug: pegaspargase;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Methotrexate;   Drug: Dexamethasone;   Drug: Thalidomide
Outcome Measures: Efficacy Outcome Measure;   Safety/Adverse Event Outcome Measure
19 Unknown  Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Thalidomide;   Drug: idarubicin
Outcome Measures: Induction therapy: response rate, overall survival, death rate;   Maintenance therapy: progression-free survival, overall survival, number of patients discontinuing therapy due to toxicity;   Induction therapy: number of patients discontinuing therapy due to toxicity, number of patients experiencing toxicity grade 3 or 4;   Maintenance therapy: dose intensity, number of patients experiencing toxicity grade 3 or 4
20 Recruiting Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI;   Procedure: auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide
Outcome Measures: Event-free survival 4 years after auto-allo/ auto-auto Tandem-SCT. Any of the following will be considered an endpoint event: recurrence or progression of primary disease, disease related mortality, or treatment related mortality.;   Incidence of acute GvHD;   Incidence of chronic GvHD;   Toxicity of conditioning regimen and of maintenance therapy;   cumulative incidence of relapse;   Disease related mortality;   Treatment related mortality;   overall survival

These studies may lead to new treatments and are adding insight into Thalidomide etiology and treatment.

A major focus of Thalidomide research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Thalidomide